A Next-Generation Bispecific Nanobody Targeting ALB and HGF for Innovative Glioblastoma Therapy

VHH-P856 is an advanced bispecific nanobody program designed to target both albumin (ALB) and hepatocyte growth factor (HGF) in the context of glioblastoma. This fully humanized single-domain antibody construct leverages the unique features of nanobodies for therapeutic intervention and is currently in the Biological Testing development phase. By engaging albumin (ALB) and hepatocyte growth factor (HGF), VHH-P856 offers a dual-targeting approach with the potential to address critical pathological mechanisms in glioblastoma, supporting its promise as a novel and versatile therapeutic candidate.

Licensing Opportunity

VHH-P856 is currently available for out-licensing opportunities. We invite industry partners to collaborate in the further development and commercialization of this innovative bispecific nanobody program for glioblastoma.

Development Phase

Modality

VHH-P856 is engineered as a bispecific construct composed of two camelid-derived single-domain antibodies (nanobodies): one directed against HGF and the other against ALB, connected by a flexible peptide linker. The nanobody format imparts a lightweight, monomeric structure that improves tissue penetration, especially within the dense and heterogeneous environment of glioblastoma. Nanobodies offer inherent thermal and chemical stability, high solubility, and the ability to reach targets inaccessible to conventional antibodies. The bispecific architecture not only enables simultaneous modulation of two disease-relevant pathways but also may facilitate enhanced pharmacokinetics in the central nervous system, providing a strategically advantageous approach for treating glioblastoma.

Target

ALB and HGF are central to the biology and progression of glioblastoma. ALB, a major plasma protein, is widely abundant in blood and facilitates drug transport and half-life extension for therapeutics. HGF is a critical signaling growth factor implicated in cell proliferation, survival, and motility, and is upregulated in several malignancies, including glioblastoma. Both ALB and HGF are expressed in various tissues, but within the tumor microenvironment of glioblastoma, HGF can drive invasiveness and resistance to treatments. ALB targeting supports improved pharmacokinetics, while HGF intervention directly addresses tumor growth and dissemination. VHH-P856's concurrent targeting of ALB and HGF creates a compelling dual-action mechanism, offering notable strategic value for malignant glioblastoma intervention.

Mechanism of Action

VHH-P856 exerts its therapeutic effect through dual mechanisms: selective binding to HGF to modulate proliferative and invasive signaling pathways in glioblastoma, and engagement with ALB to potentially enhance serum half-life and tissue distribution. By disrupting HGF-triggered signaling, VHH-P856 can interfere with tumor cell migration and survival processes. The ALB-binding domain capitalizes on albumin's natural pharmacokinetic advantages, optimizing systemic exposure and potentially improving delivery to the brain. The nanobody platform also lends itself to modular engineering, providing a basis for further development into antibody-drug conjugates or next-generation bispecifics that could enable targeted payload delivery and multifunctional signaling blockade, establishing new possibilities in precision oncology.

Glioblastoma

Glioblastoma is an aggressive primary brain tumor characterized by rapid growth, diffuse infiltration, and poor prognosis. It primarily affects adults and is associated with high morbidity and mortality worldwide. Current approaches to treatment encompass surgical resection, radiation therapy, and chemotherapy, with the addition of targeted therapies in some cases. Despite these interventions, median survival remains limited due to the tumor's resistance to standard modalities, its remarkable heterogeneity, and the formidable challenge of drug delivery across the blood-brain barrier. Novel biologicals with enhanced penetration and dual-targeting capabilities, such as VHH-P856, could address several of these obstacles by modulating relevant pathways (ALB and HGF) and improving therapeutic exposure within the tumor. There remains a significant unmet medical need for durable and effective therapeutic options in glioblastoma, positioning VHH-P856 as a promising next-generation candidate.